MMJ Recs

MARCH 25, 2022

Patient drives are like pop-up day events, during which many people can avail of quick and easy appointments for MMJ cards if they have a qualifying condition. There may be other qualifying conditions for a NY MMJ card. These can be discussed during your consultation with a licensed MMJRecs NY state physician.

Patients 52

Patients Conditions Chronic Pain Dispensary 52

PrestoDoctor

JUNE 2, 2020

The reason for this explosion of medical marijuana use is that many people are turning to it for relief from pain, insomnia, anxiety, epilepsy, and a host of other issues. Even in this event, you might still want to see a medical marijuana doctor. In some instances, they might refer you to a marijuana clinic.

Marijuana 52

Marijuana Epilepsy Conditions Chronic Pain 52

Cannabis Law Report

DECEMBER 1, 2021

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 24, 2021

. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D., President, Director and Chief Medical Officer. Investor Contact: Robert Schatz.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

MMJ Recs

OCTOBER 2, 2023

California has been a trailblazer in the realm of medical marijuana, offering patients access to a variety of treatment options. If the doctor determines that medical cannabis is a suitable treatment option, they will provide a recommendation for the patient. You can find CA medical marijuana doctors online on sites like MMJRecs.

Dispensary 52

Dispensary Patients Environment Conditions 52

Cannabis Law Report

OCTOBER 19, 2021

MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

MMJ Recs

MARCH 2, 2024

Observing discretion in discussions regarding medical conditions and treatment enhances privacy and respect among patrons. A: Qualifying medical conditions in Ohio include cancer, PTSD, chronic pain, epilepsy, and more. Q: What medical conditions qualify for medical marijuana use in Ohio?

Dispensary 52

Dispensary Patients Marijuana Education 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. For example, most statin drugs can cause memory issues, muscle pain, fatigue and muscle weakness. Epilepsy & behavior case reports 9 (2018): 10. Medicines 6.1

CBD 98

CBD THC Conditions Medicine 98

Otherside Farms

JANUARY 17, 2020

The Food and Drug Administration allows the use of CBD to treat pain, anxiety, depression, nausea, and some types of epilepsy. CBD is therefore convenient to those that suffer nausea from chemotherapy treatment and other conditions. CBD can quell pain; it is not easy to have a good appetite when you are in pain.

Food 52

Food Research and Development Seed-To-Sale Vaping 52

Cannabis Law Report

NOVEMBER 23, 2021

It’s also important to note that MYMD-1 shows promise in pre-clinical studies as a treatment for immune diseases including rheumatoid arthritis, multiple sclerosis, and Hashimoto’s thyroiditis, and as an anti-fibrotic and anti-proliferation therapeutic.”. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

The issued claims protect the use of MYMD-1 in a method of treatment for the progressive and generalized loss of skeletal muscle mass and strength known as sarcopenia. MYMD-1 also shows promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

MYMD-1’s primary purpose is to slow the aging process and extend human lifespan, but it is also showing promise as a potential treatment for COVID-19-related complications, and as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. For example, most statin drugs can cause memory issues, muscle pain, fatigue and muscle weakness. Epilepsy & behavior case reports 9 (2018): 10. [4] 2014): 86-95. [2]

CBD 52

CBD THC Conditions Medicine 52

Veriheal

OCTOBER 5, 2020

This bill also allows for dispensaries to “provide, disseminate, and publish educational and scientific material related to medical cannabis and its approved products and sponsor events about medical cannabis”. . Summary of Hawaiian Cannabis Regulations. Act 228 allows for the growth of cannabis for medical purposes. .

Edibles 52

Edibles Legalization Decriminalization Consumption 52

Cannabis Law Report

MAY 6, 2022

Examples of sellers’ language the FDA views as illegal are the following: “Our line of …CBD oil … is great for insomnia, epilepsy, MS, schizophrenia, and chronic pain.”. Taking CBD can relieve pain.”. “In Delta-8 is known to be successful in many cancer treatments.”.

THC 52

THC CBD Media Food 52

Cannabis Law Report

OCTOBER 26, 2021

MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. Nanomerics has initiated preclinical studies of VRP324. Christopher M. Chipman, CPA. Chief Financial Officer.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

FEBRUARY 18, 2020

As of January 2020, the list includes several debilitating diseases and life-threatening conditions, as well as other conditions that cause severe suffering, such as cancer, HIV , Parkinson’s, epilepsy, etc. In the event you’re not approved for certification, the appointment fee will be returned. Apply for a Marijuana Card.

Marijuana 59

Marijuana Consumption Dispensary Vaping 59

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical pain up to 4 days post surgery as compared with vehicle treated animals. TEL AVIV, Israel , Aug. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

SEPTEMBER 23, 2019

The AAFP urges its members to be involved in the diagnosis, treatment, and prevention of substance use, as well as secondary diseases impacted or caused by use. The AAFP recognizes the benefits of intervention and treatment for the recreational use of marijuana, in lieu of incarceration, for all individuals, including youth.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

MARCH 6, 2020

KLS-13019 is Kannalife’s leading proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). This is the sixth patent grant that Kannalife has received. About KLS-13019.

Research and Development 59

Research and Development Marijuana Pharmaceutical Supply Chain 59

Cannabis Law Report

OCTOBER 6, 2021

Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children, a rare pediatric disease.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

DECEMBER 28, 2021

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. There were no treatment-related clinical observations, changes in body weight, or dermal irritation observed. Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. for its MET for the nasal delivery of cannabidiol (CBD) for the management of epilepsy in children (rare pediatric disease) and adults.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 8, 2021

Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Christopher M.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). Cancer pain.

Research and Development 52

Research and Development Medicine Access Media 52

CannaTech

JUNE 30, 2019

Patients over the age of 18 (excepting children with severe epilepsy). Neurological indications such as epilepsy, Parkinson’s. Severe epilepsy in minors. Furthermore, specific strains targeting conditions including refractory epilepsy have been available in the interim. Registered by a specialist physician.

Patients 90

Patients Oil Epilepsy Strains 90

Greencamp

DECEMBER 4, 2018

Anandamide’s “forgetting” function is also very important for traumatic and extremely stressful events, and people suffering from PTSD have a very hard time disconnecting from the trauma they’ve experienced. Chronic Pain. This is why CBD works wonders for anxiety ( 4 ) and also PTSD patients. Irritable Bowel Syndrome (IBS).

Cannabinoids 107

Cannabinoids Research and Development Conditions THC 107

CannaTech

JUNE 30, 2019

Patients over the age of 18 (excepting children with severe epilepsy). Neurological indications such as epilepsy, Parkinson’s. Severe epilepsy in minors. Furthermore, specific strains targeting conditions including refractory epilepsy have been available in the interim. Registered by a specialist physician.

Patients 40

Patients Oil Epilepsy Strains 40

Green Relief

MAY 13, 2018

It is the most commonly identified cause of epilepsy among adults. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. Triggered by concussions from car accidents, falls, violent contact sports, explosives or by gunshot and stab wounds, TBI affects 1.7 million Americans annually.

THC 64

THC CBD Cannabinoids Research and Development 64

The Cannigma

OCTOBER 8, 2021

A January, 2019 event held at the Senedd – the Welsh Parliament – included a call from Arfon Jones, a North Wales Police and Crime Commissioner, to decriminalize cannabis. The physician will look at the patient’s medical record and ask why previous treatments didn’t work and how the health condition affects the patient’s life.

Legalization 52

Legalization Medicine Conditions Patients 52

Healer

JUNE 28, 2019

‘Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.’ Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. 006), mean worst pain (P =.011), Abstract: Medical Study .

Cannabinoids 52

Cannabinoids THC Therapy Patients 52

Cannabis Law Report

OCTOBER 17, 2019

Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. They don’t want to disallow access to the only thing that may stop epileptic seizures in children or is part of a patient’s treatment plan.”

Law 40

Law Seed-To-Sale Hemp Recreational 40